NEW YORK (GenomeWeb News) – Cepheid today announced the US Food and Drug Administration has cleared the GeneXpert Infinity-80 System in conjunction with its Xpert Flu test.

The GeneXpert Infinity-80 is a high-throughput, fully automated system designed to deliver around-the-clock results for various clinical testing applications, the Sunnyvale, Calif.-based company said. The system is designed to adapt to any workflow requirement including on-demand, batch, or STAT testing, and is available in configurations of 16, 24, 32, 40, 48, 56, 64, 72, and 80 modules.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.